Literature DB >> 12410472

Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci.

Aimee K Zaas1, Xiaoyan Song, Pamela Tucker, Trish M Perl.   

Abstract

Vancomycin-resistant Enterococcus faecium (VRE) is a common nosocomial isolate, especially among patients with cancer. VRE infections have substantial attributable mortality among patients with cancer. The purpose of this study was to identify risk factors for developing bloodstream infection with VRE in patients with cancer who are colonized with VRE. VRE colonization was prospectively identified in 197 patients with cancer during 4-year period, of whom 179 (91%) had complete records for evaluation. Of these 179 patients, 24 (13.4%) developed hospital-acquired VRE bloodstream infections. Risk factors for VRE bloodstream infection included vancomycin use (relative risk [RR], 1.98; 95% confidence interval [CI], 1.25-3.14), diabetes mellitus (RR, 3.91; 95% CI, 1.20-12.77), gastrointestinal procedures (RR, 4.56; 95% CI, 1.05-19.7), and acute renal failure (RR, 3.10; 95% CI, 1.07-8.93). Strategies for preventing VRE bloodstream infection in VRE-colonized patients with cancer should include limiting vancomycin use and, perhaps, gastrointestinal procedures.

Entities:  

Mesh:

Year:  2002        PMID: 12410472     DOI: 10.1086/342904

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  30 in total

1.  Acquisition and duration of vancomycin-resistant enterococcal carriage in relation to strain type.

Authors:  E M Mascini; K P Jalink; T E M Kamp-Hopmans; H E M Blok; J Verhoef; M J M Bonten; A Troelstra
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

2.  Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies.

Authors:  B J Liss; J J Vehreschild; O A Cornely; M Hallek; G Fätkenheuer; H Wisplinghoff; H Seifert; M J G T Vehreschild
Journal:  Infection       Date:  2012-06-05       Impact factor: 3.553

3.  Risk of postdischarge infection with vancomycin-resistant enterococcus after initial infection or colonization.

Authors:  Rupak Datta; Susan S Huang
Journal:  Infect Control Hosp Epidemiol       Date:  2010-10-27       Impact factor: 3.254

4.  Functional disability and nursing resource use are predictive of antimicrobial resistance in nursing homes.

Authors:  Lillian Min; Andrzej Galecki; Lona Mody
Journal:  J Am Geriatr Soc       Date:  2015-04-08       Impact factor: 5.562

5.  Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy.

Authors:  Graeme N Forrest; Mary-Claire Roghmann; Latoya S Toombs; Jennifer K Johnson; Elizabeth Weekes; Durry P Lincalis; Richard A Venezia
Journal:  Antimicrob Agents Chemother       Date:  2008-07-28       Impact factor: 5.191

6.  Vancomycin flush as antibiotic prophylaxis for early catheter-related infections: a cost-effectiveness analysis.

Authors:  Nicolas Penel; Yazdan Yazdanpanah
Journal:  Support Care Cancer       Date:  2008-07-29       Impact factor: 3.603

7.  Evaluation of a chromogenic agar under development to screen for VRE colonization.

Authors:  George Kallstrom; Christopher D Doern; W Michael Dunne
Journal:  J Clin Microbiol       Date:  2010-01-20       Impact factor: 5.948

8.  Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient.

Authors:  Imad Dibo; Satish K Pillai; Howard S Gold; Maria R Baer; Meir Wetzler; James L Slack; Peggy A Hazamy; Donna Ball; Chiu Bin Hsiao; Philip L McCarthy; Brahm H Segal
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

9.  Considerations for Empiric Antimicrobial Therapy in Sepsis and Septic Shock in an Era of Antimicrobial Resistance.

Authors:  Jeffrey R Strich; Emily L Heil; Henry Masur
Journal:  J Infect Dis       Date:  2020-07-21       Impact factor: 5.226

10.  Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE.

Authors:  John B Bossaer; Philip D Hall; Elizabeth Garrett-Mayer
Journal:  Support Care Cancer       Date:  2010-01-13       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.